ASH 2016 | Key studies on multiple myeloma presented at ASH 2016
Paul Richardson
• 3 Dec 2016
Paul Richardson, MD of Dana-Farber Cancer Institute, Boston, MA discusses key studies in multiple myeloma (MM) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Richardson discusses data presented on pembrolizumab combined with IMiDs, as well as data on venetoclax combined with bortezomib, and marizomib and pomalidomide. He also talks about the selinexor compound, which represents a novel class of drug and the combination strategies with bortezomib in the STOMP trial (NCT02343042).
